Abstract
Background: Rare diseases (RD) predominantly manifest in childhood and adolescence, are heterogeneous, multisystemic, and typically chronic, posing significant challenges for all involved. Funded by the G-BA Innovation Fund, the TRANSLATE-NAMSE project aimed to develop and test proposals for improved care for people with RD.
Objective: To develop a generic care pathway for patients of all ages with a suspected diagnosis from five defined indicator groups (rare anemias, endocrinopathies, autoinflammatory diseases, primary immunodeficiencies, and metabolic diseases), mapping the journey from confirmatory diagnostics to long-term care.
Methodology: The care pathway was presented as a general flowchart; process steps were transferred into a checklist and tested at six university sites with 587 individuals suspected of having an indicator disease.
Results: A diagnosis was established for 369 (62.9%) cases, with 25.2% achieved through innovative genetic diagnostics. 104 (17.7%) suspected diagnoses were false-positive, and 114 (19.4%) cases remained unexplained. Multiprofessional case conferences involved a median of four specialists. Care (diagnosis disclosure, training, counseling) began at a median of zero days from the diagnostic result. Caregiver satisfaction was high.
Conclusions: The TRANSLATE-NAMSE project successfully developed and tested a unique care pathway for pediatric RD in Germany. Sustainable financing in standard care is necessary to maintain this model.
Introduction
Rare diseases (RD) are a significant challenge for healthcare systems. While each individual disease is rare, they collectively affect approximately 4 million people in Germany alone. About 80% of these conditions manifest during childhood, often presenting as complex, multisystemic, and chronic disorders.
The "diagnostic odyssey"—the long, fragmented period between the onset of symptoms and a definitive diagnosis—is a well-known hurdle. However, even after a diagnosis is reached, families often face a "care gap," where the transition to specialized, multiprofessional treatment is slow and uncoordinated. This paper details the results of the TRANSLATE-NAMSE project, which established a structured "care pathway" to bridge the gap from initial suspicion to long-term management.
Methods: A Standardized Pathway
The researchers developed a generic clinical pathway designed to be applicable across various disease groups. The methodology centered on two primary tools: a visual flowchart mapping the process from evaluation of confirmatory diagnostics to the initiation of multiprofessional care, and an itemized 34-point practical checklist used by clinicians to document steps, including interdisciplinary case conferences (Fallkonferenzen), genetic counseling, and patient training.
The pathway was field-tested at six German university medical centers. A key feature was the use of Whole Exome Sequencing (WES) as an "innovative diagnostic" step when standard methods failed. The study focused on five "indicator groups": rare anemias, endocrinopathies, autoinflammatory diseases, primary immunodeficiencies, and metabolic diseases.
Key Results and Diagnostic Success
The study evaluated a cohort of 587 patients. A specific diagnosis was confirmed in 62.9% (369/587) of cases. Of those confirmed diagnoses, 25.2% were reached specifically through innovative genetic testing (WES).
Efficiency of Care Transition
One of the most striking findings was the "Zero-Day" Transition: the median time between the availability of a diagnostic result and the start of specialized care (information, training, and counseling) was 0 days. This suggests that a structured pathway can eliminate the traditional lag time in starting treatment.
Interdisciplinary Synergy
The median number of specialists involved in case conferences was four. This multiprofessional approach is essential for diseases that affect multiple organ systems simultaneously.
The Value of "Ruling Out"
Approximately 17.7% of cases were identified as "false positives" (the suspected RD was ruled out). In the context of rare diseases, a definitive "no" is a valuable clinical outcome that prevents unnecessary treatments and allows clinicians to pivot to other diagnostic possibilities.
Patient and Caregiver Impact
Caregivers rated the pathway with a median grade of 2 (on a 1–5 scale, where 1 is "very good"), indicating high levels of trust and satisfaction with the coordinated care. Comprehensive care was a hallmark of the project: 94.3% of families received a formal diagnosis disclosure talk, and 65.6% received specific behavioral training to manage the condition at home.
Conclusion
The TRANSLATE-NAMSE project successfully developed and field-tested a standardized, multiprofessional clinical pathway for children with suspected rare diseases. By integrating interdisciplinary case conferences and innovative genetic testing, the project achieved a high diagnostic rate and ensured immediate transition to specialized care.
However, the intensive coordination required—specifically the time for interdisciplinary case conferences and dedicated case managers—is not yet fully covered by standard health insurance reimbursement models in Germany. Future work must focus on advocating for the integration of these specialized centers into regular healthcare financing to ensure the sustainability of this improved care model.
Summary updated